Penumbra, Inc. (PEN): Price and Financial Metrics


Penumbra, Inc. (PEN): $272.16

-1.10 (-0.40%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

PEN POWR Grades


  • PEN scores best on the Growth dimension, with a Growth rank ahead of 99.76% of US stocks.
  • The strongest trend for PEN is in Growth, which has been heading up over the past 31 weeks.
  • PEN ranks lowest in Value; there it ranks in the 34th percentile.

PEN Stock Summary

  • PEN's one year PEG ratio, measuring expected growth in earnings next year relative to current common stock price is 1,243.26 -- higher than 96.27% of US-listed equities with positive expected earnings growth.
  • PEN's price/sales ratio is 17.02; that's higher than the P/S ratio of 88.16% of US stocks.
  • In terms of twelve month growth in earnings before interest and taxes, Penumbra Inc is reporting a growth rate of -153.22%; that's higher than just 13.64% of US stocks.
  • Stocks with similar financial metrics, market capitalization, and price volatility to Penumbra Inc are CDMO, VERU, OPRX, PKOH, and ALTR.
  • PEN's SEC filings can be seen here. And to visit Penumbra Inc's official web site, go to www.penumbrainc.com.

PEN Price Target

For more insight on analysts targets of PEN, see our PEN price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $315.40 Average Broker Recommendation 1.29 (Strong Buy)

PEN Stock Price Chart Interactive Chart >

Price chart for PEN

PEN Price/Volume Stats

Current price $272.16 52-week high $320.00
Prev. close $273.26 52-week low $163.49
Day low $270.32 Volume 118,156
Day high $275.34 Avg. volume 378,410
50-day MA $272.20 Dividend yield N/A
200-day MA $243.73 Market Cap 9.93B

Penumbra, Inc. (PEN) Company Bio


Penumbra Inc. is a specialty interventional therapies company that develops and markets innovative medical devices to treat challenging medical conditions with significant unmet clinical needs. The company was founded in 2004 and is based in Alameda, CA.


PEN Latest News Stream


Event/Time News Detail
Loading, please wait...

PEN Latest Social Stream


Loading social stream, please wait...

View Full PEN Social Stream

Latest PEN News From Around the Web

Below are the latest news stories about Penumbra Inc that investors may wish to consider to help them evaluate PEN as an investment opportunity.

Penumbra Consensus Indicates Potential 11.1% Upside

Penumbra with ticker code (PEN) have now 5 analysts in total covering the stock. The consensus rating is ''Buy''. The target price ranges between 335 and 291 with a mean TP of 315.4. Now with the previous closing price of 283.78 this now indicates there is a potential upside of 11.1%. The 50 day MA is 268.93 while the 200 day moving average is 251.25. The market cap for the company is $10,442m. You can visit the company''s website by visiting: /> [stock_market_widget type="chart" symbol="PEN" chart="bar" range="6mo" interval="1d" line-color="rgb(49, 125, 189)"] Penumbra designs, develops, manufactures, and markets medical devices in the United States, Europe, Canada, Australia, and internationally. The company offers aspiration based thrombectomy systems and accessory devices, including...

DirectorsTalk | June 11, 2021

Wells Fargo Sticks to Their Buy Rating for Penumbra (PEN)

In a report issued on June 3, Larry Biegelsen from Wells Fargo maintained a Buy rating on Penumbra (PEN). The companys shares closed The post Wells Fargo Sticks to Their Buy Rating for Penumbra (PEN) appeared first on Smarter Analyst .

Smarter Analyst | June 8, 2021

Peripheral Vascular Clot Management Interventions Market Analysis and Global Outlook 2021 to 2026 - Boston Scientific Corporation, Penumbra Inc, Medtronic

MarketInsightsReports has published a report titled Peripheral Vascular Clot Management Interventions Market research report 2021 that is a detailed observation of several aspects, including value, volume, recent market trends, and different methodologies implemented by the primary market players. The report

OpenPR | June 7, 2021

Penumbra Inc (PEN) Q1 2021 Earnings Call Transcript

At this time, I would like to welcome everyone to Penumbra's First Quarter 2021 Conference Call. Thank you, operator, and thank you all for joining us on today's call to discuss Penumbra's earnings release for the first quarter of 2021.

Yahoo | May 5, 2021

Penumbra (PEN) Q1 Earnings and Revenues Surpass Estimates

Penumbra (PEN) delivered earnings and revenue surprises of 145.45% and 10.41%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

Yahoo | May 4, 2021

Read More 'PEN' Stories Here

PEN Price Returns

1-mo 10.80%
3-mo 2.02%
6-mo 49.54%
1-year 57.24%
3-year 77.48%
5-year 363.41%
YTD 55.52%
2020 6.53%
2019 34.43%
2018 29.86%
2017 47.49%
2016 18.57%

Continue Researching PEN

Here are a few links from around the web to help you further your research on Penumbra Inc's stock as an investment opportunity:

Penumbra Inc (PEN) Stock Price | Nasdaq
Penumbra Inc (PEN) Stock Quote, History and News - Yahoo Finance
Penumbra Inc (PEN) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.8091 seconds.